J&J Fined $1.2B In Ark.'s Risperdal Marketing Suit

Law360, New York (April 11, 2012, 1:39 PM EDT) -- An Arkansas judge fined Johnson & Johnson and a subsidiary more than $1.2 billion on Wednesday after a jury sided with Arkansas in a suit claiming the companies committed Medicaid fraud through illegal marketing of antipsychotic drug Risperdal.

Arkansas brought the suit in November 2007 to recover the money it paid to provide Risperdal to patients through Medicaid and other programs. It argued that J&J and its unit Janssen Pharmaceuticals Inc. misrepresented the drug's risks to patients and promoted its use for unnecessary medical conditions....
To view the full article, register now.